Latanoprostene bunod

Summary of Evidence

Latanoprost bunod vs Timolol

At all 9 time points (IOP was measured at 8 am, 12 pm, and 4 pm of each follow-up visit ), the mean IOP in the study eye was significantly lower in the LBN 0.024% group than in the timolol 0.5% group.(APOLLO, 2016) {Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016 May;123(5):965-73.}

Mean IOP reduction in the LBN group was significantly greater than timolol at all but the first time point in this study (week 2, 8 AM).(LUNAR, 2016) {Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol. 2016 Aug;168:250-259.}

Evidence

1. Background

2. Safety and efficacy

2.1 Comparative effectiveness

2.1.1 Latanoprostene bunod vs timolol

Clinical Trial

2016 Weinreb et.al. (APOLLO)

Article link | Archive link | Metrics

2016
Clinical Trial

At all 9 time points (IOP was measured at 8 am, 12 pm, and 4 pm of each follow-up visit ), the mean IOP in the study eye was significantly lower in the LBN 0.024% group than in the timolol 0.5% group. {Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016 May;123(5):965-73.}

Randomized controlled trial of Latanoprostene bunod ophthalmic solution 0.024% vs timolol 0.5% in patients with bilateral open angle glaucoma or ocular hypertension (387 patients)

Outcomes	LBN 0.024%	Timolol 0.5%
Proportion of subjects with mean IOP ≤18 mmHg	22.9%	11.3%
Proportion of subjects with IOP reduction ≥25%	34.9%	19.5%

Weinreb et.al. (APOLLO)
Journal full text Archive Metrics

Clinical Trial

2016 Medeiros et.al. (LUNAR)

Article link | Archive link | Metrics

2016
Clinical Trial

Mean IOP reduction in the LBN group was significantly greater than timolol at all but the first time point in this study (week 2, 8 AM). {Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol. 2016 Aug;168:250-259.}

Randomized controlled trial of Latanoprostene bunod ophthalmic solution 0.024% vs timolol 0.5% in patients with bilateral open angle glaucoma or ocular hypertension (387 patients)

Outcomes	LBN 0.024%	Timolol 0.5%
Proportion of subjects with mean IOP ≤18 mmHg	17.1%	11.1%
Proportion of subjects with IOP reduction ≥25%	31.0%	18.5%

Medeiros et.al. (LUNAR)
Journal full text Archive Metrics

References

Comments

Subscribe

0 Comments

Inline Feedbacks

View all comments